Goodwin Biotechnology, Panacea Partner
Goodwin Biotechnology, Inc., a biological contract development and manufacturing organization specializing in bioprocess development and GMP manufacturing using mammalian cell culture expression systems and bioconjugation technologies, was selected by Panacea Pharmaceuticals, Inc. to complete a fill /finish project, as well as a quality control release and stability testing for a therapeutic, nanoparticle cancer vaccine based on the human aspartyl (asparaginyl) Î²â€hydroxylase (HAAH) tumorâ€specific protein to support Phase I clinical trials in patients with various solid tumor cancers.
In addition to providing bioprocessing services, Goodwin Biotechnology operates an ISO5 cGMP filling suite that can accommodate liquid filling for various configurations. Panacea Pharmaceuticals, Inc. was founded in 1999 to discover, develop, and commercialize novel therapeutic and diagnostic products for oncology and diseases of the central nervous system.
Source: Goodwin Biotechnology